Agree Hevlet - the most of us know the company is not great at how they release announcements. With this being said it is nice to see progression with the clinical trial, and upon official results of the trial (if in line with the early 2021 SubB2M results we should surely see some share price appreciation.
Ann: CEO AGM Presentation, page-8
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.035(6.25%) |
Mkt cap ! $65.61M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 59.5¢ | 56.0¢ | $20.62K | 36.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 446 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 30002 | 3 |
View Market Depth
| Last trade - 15.57pm 23/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |